Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes.

Scientific reports - 17 Aug 2018

Kim Se-Hyung, Byeon Ji-Young, Kim Young-Hoon, Lee Choong-Min, Lee Yun Jeong, Jang Choon-Gon, Lee Seok-Yong

Abstract excerpt

Atomoxetine is a norepinephrine reuptake inhibitor indicated in the treatment of attention-deficit/hyperactivity disorder. It is primarily metabolized by CYP2D6 to its equipotent metabolite, 4-hydroxyatomoxetine, which promptly undergoes further glucuronidation to an inactive 4-HAT-O-glucuronide. Clinical trials have shown that decreased CYP2D6 activity leads to substantially elevated atomoxetine exposure and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Area Under Curve
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Models, Theoretical

Share to Pharmacogenetics

Share to Pharmacogenomic Variants

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 30120390
DOI: 10.1038/s41598-018-30841-8
PMCID: PMC6098032

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes.PMID 30120390Read ↗

Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites.Semantic proximity Read ↗

Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6.Semantic proximity Read ↗

Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.Semantic proximity Read ↗

Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.Semantic proximity Read ↗

Pharmacokinetics, safety, and tolerability of atomoxetine and effect of CYP2D6*10/*10 genotype in healthy Japanese men.Semantic proximity Read ↗

Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 alleleSemantic proximity Read ↗

Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics.Semantic proximity Read ↗

Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes.Semantic proximity Read ↗

Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for <scp>Cytochrome P450 (<i>CYP</i>)</scp><i>2D6</i> Genotype and Atomoxetine TherapySemantic proximity Read ↗

Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD.Semantic proximity Read ↗

Effect of CYP2D6 and CYP2C19 genotypes on atomoxetine serum levels -- a study based on therapeutic drug monitoring dataSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.